Cisapride treatment for gastro‐oesophageal reflux in children

Cristina Augood; Suzanna MacLennan; Ruth E Gilbert; Stuart Logan

doi:10.1002/14651858.CD002300

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Guías
Temas

Revisiones y protocolos relacionados

Topics

Temas

Analysis 1.1

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 1 'Worse, same or slight improvement' vs 'moderate or excellent improvement'.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 2 Reflux index.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 3 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Main analysis for Cisapride vs Gaviscon/Carobel, Outcome 1 'Worse, same or slight improvement' vs 'moderate or excellent improvement'.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.1

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 1 Best case scenario.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.2

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 2 Worst case scenario.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.3

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 3 Change in outcome definition: 'any symptoms' vs 'no symptoms' at end of treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Main analysis for Cisapride vs placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 'Worse, same or slight improvement' vs 'moderate or excellent improvement' Show forest plot	7	236	Odds Ratio (M‐H, Random, 95% CI)	0.34 [0.10, 1.19]

2 Reflux index Show forest plot	5	176	Mean Difference (IV, Random, 95% CI)	‐6.49 [‐10.13, ‐2.85]

3 Adverse events Show forest plot	4	190	Odds Ratio (M‐H, Random, 95% CI)	1.86 [0.88, 3.93]

Comparison 1. Main analysis for Cisapride vs placebo

Ir a la tabla de la revisión

Comparison 2. Main analysis for Cisapride vs Gaviscon/Carobel

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 'Worse, same or slight improvement' vs 'moderate or excellent improvement' Show forest plot	1	50	Odds Ratio (M‐H, Random, 95% CI)	3.26 [0.93, 11.38]

Comparison 2. Main analysis for Cisapride vs Gaviscon/Carobel

Ir a la tabla de la revisión

Comparison 3. Sensitivity analyses for Cisapride vs placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Best case scenario Show forest plot	7	290	Odds Ratio (M‐H, Random, 95% CI)	0.21 [0.08, 0.54]

2 Worst case scenario Show forest plot	7	290	Odds Ratio (M‐H, Random, 95% CI)	0.70 [0.18, 2.65]

3 Change in outcome definition: 'any symptoms' vs 'no symptoms' at end of treatment Show forest plot	4	139	Odds Ratio (M‐H, Random, 95% CI)	0.19 [0.07, 0.51]

Comparison 3. Sensitivity analyses for Cisapride vs placebo

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet